School of Chemistry, SFI Tetrapyrrole Laboratory, Trinity Biomedical Science Institute , Trinity College Dublin, the University of Dublin , 152-160 Pearse Street , Dublin 2 , Ireland.
Department of Chemistry, Faculty of Science , Arak University , Arak 38156-8-8349 , Iran.
Biomacromolecules. 2018 May 14;19(5):1592-1601. doi: 10.1021/acs.biomac.8b00293. Epub 2018 Apr 6.
A novel poly( N-isopropylacrylamide) (PNIPAM) hydrogel containing different photosensitizers (protoporphyrin IX (PpIX), pheophorbide a (Pba), and protoporphyrin IX dimethyl ester (PpIX-DME)) has been synthesized with a significant improvement in water solubility and potential for PDT applications compared to the individual photosensitizers (PSs). Conjugation of PpIX, Pba, and PpIX-DME to the poly( N-isopropylacrylamide) chain was achieved using the dispersion polymerization method. This study describes how the use of nanohydrogel structures to deliver a photosensitizer with low water solubility and high aggregation tendencies in polar solvents overcomes these limitations. FT-IR spectroscopy, UV-vis spectroscopy, H NMR, fluorescence spectroscopy, SEM, and DLS analysis were used to characterize the PNIPAM-photosensitizer nanohydrogels. Spectroscopic studies indicate that the PpIX, Pba, and PpIX-DME photosensitizers are covalently conjugated to the polymer chains, which prevents aggregation and thus allows significant singlet oxygen production upon illumination. Likewise, the lower critical solution temperature was raised to ∼44 °C in the new PNIPAM-PS hydrogels. The PNIPAM hydrogels are biocompatible with >90% cell viability even at high concentrations of the photosensitizer in vitro. Furthermore, a very sharp onset of light-dependent toxicity for the PpIX-based nanohydrogel in the nanomolar range and a more modest, but significant, photocytotoxic response for Pba-PNIPAM and PpIX-DME-PNIPAM nanohydrogels suggest that the new hydrogels have potential for applications in photodynamic therapy.
一种新型的聚(N-异丙基丙烯酰胺)(PNIPAM)水凝胶,含有不同的光敏剂(原卟啉 IX(PpIX)、叶绿素 a(Pba)和原卟啉 IX 二甲酯(PpIX-DME)),与单独的光敏剂(PS)相比,其水溶性显著提高,有潜力应用于光动力疗法。使用分散聚合方法将 PpIX、Pba 和 PpIX-DME 接枝到聚(N-异丙基丙烯酰胺)链上。本研究描述了如何使用纳米水凝胶结构来克服这些限制,将具有低水溶性和在极性溶剂中高聚集倾向的光敏剂递送到细胞中。傅里叶变换红外光谱(FT-IR)、紫外-可见光谱(UV-vis)、H 核磁共振(NMR)、荧光光谱、扫描电子显微镜(SEM)和动态光散射(DLS)分析用于表征 PNIPAM-光敏剂纳米水凝胶。光谱研究表明,PpIX、Pba 和 PpIX-DME 光敏剂通过化学键合到聚合物链上,从而防止聚集,因此在光照下可以产生大量的单线态氧。同样,新的 PNIPAM-PS 水凝胶的低临界溶液温度提高到约 44°C。PNIPAM 水凝胶具有生物相容性,即使在体外高浓度的光敏剂下,细胞存活率也超过 90%。此外,基于 PpIX 的纳米水凝胶在纳摩尔范围内具有非常明显的光依赖性毒性,而 Pba-PNIPAM 和 PpIX-DME-PNIPAM 纳米水凝胶则具有适度但显著的光细胞毒性反应,这表明新的水凝胶在光动力疗法中有应用潜力。